Abstract 1422: Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Abstract T cells modified to express chimeric antigen receptor (CAR) targeting CD19 have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymph...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 79; no. 13_Supplement; p. 1422 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.07.2019
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-NHL) patients. However, a subset of patients who relapse after CD19CAR T-cell therapy have outgrowth of CD19-negative tumor cells. Hence, development of alternative CARs targeting other B-cell markers represents an unmet medical need for B-ALL and B-NHL. Here, we confirmed previous data by showing that B-NHL overall have high expression of CD37. A second generation CD37CAR was designed and its efficacy in T cells was compared to that of CD19CAR. In vitro assessment of cytotoxicity and T-cell function upon co-culture of the CAR T cells with different target B-cell lymphoma cell lines demonstrated comparable efficacy between the two CARs. In an aggressive B-cell lymphoma xenograft model, CD37CAR T cells were as potent as CD19CAR T cells in controlling tumor growth. In a second xenograft model, using U2932 lymphoma cells containing a CD19-negative subpopulation, CD37CAR T cells efficiently controlled tumors and cured the mice while CD19CAR T cells had limited effect. We further show that, unlike CD19CAR, CD37CAR was not sensitive to antigen masking. Finally, CD37CAR reactivity was restricted to B-lineage cells. Collectively, our results demonstrated that CD37CAR T cells effectively can eradicate B-cell lymphoma tumors also when CD19 antigen expression is lost, and support further clinical testing for patients with relapsed/refractory B-NHL.
Citation Format: Pierre Dillard, Hakan Köksal, Sarah Josefsson, Solrun Melkorka Maggadottir, Sylvie Pollmann, Anne Fåne, Yngvild Nuvin Blaker, Klaus Beiske, Kanutte Huse, Ane Kolstad, Harald Holte, Gunnar Kvalheim, Erlend Bremertun Smeland, June Myklebust, Else Marit Inderberg, Sebastien Wälchli. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1422. |
---|---|
AbstractList | Abstract
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-NHL) patients. However, a subset of patients who relapse after CD19CAR T-cell therapy have outgrowth of CD19-negative tumor cells. Hence, development of alternative CARs targeting other B-cell markers represents an unmet medical need for B-ALL and B-NHL. Here, we confirmed previous data by showing that B-NHL overall have high expression of CD37. A second generation CD37CAR was designed and its efficacy in T cells was compared to that of CD19CAR. In vitro assessment of cytotoxicity and T-cell function upon co-culture of the CAR T cells with different target B-cell lymphoma cell lines demonstrated comparable efficacy between the two CARs. In an aggressive B-cell lymphoma xenograft model, CD37CAR T cells were as potent as CD19CAR T cells in controlling tumor growth. In a second xenograft model, using U2932 lymphoma cells containing a CD19-negative subpopulation, CD37CAR T cells efficiently controlled tumors and cured the mice while CD19CAR T cells had limited effect. We further show that, unlike CD19CAR, CD37CAR was not sensitive to antigen masking. Finally, CD37CAR reactivity was restricted to B-lineage cells. Collectively, our results demonstrated that CD37CAR T cells effectively can eradicate B-cell lymphoma tumors also when CD19 antigen expression is lost, and support further clinical testing for patients with relapsed/refractory B-NHL.
Citation Format: Pierre Dillard, Hakan Köksal, Sarah Josefsson, Solrun Melkorka Maggadottir, Sylvie Pollmann, Anne Fåne, Yngvild Nuvin Blaker, Klaus Beiske, Kanutte Huse, Ane Kolstad, Harald Holte, Gunnar Kvalheim, Erlend Bremertun Smeland, June Myklebust, Else Marit Inderberg, Sebastien Wälchli. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1422. |
Author | Inderberg, Else Marit Köksal, Hakan Kolstad, Ane Holte, Harald Huse, Kanutte Fåne, Anne Josefsson, Sarah Kvalheim, Gunnar Blaker, Yngvild Nuvin Maggadottir, Solrun Melkorka Pollmann, Sylvie Beiske, Klaus Dillard, Pierre Myklebust, June Wälchli, Sebastien Smeland, Erlend Bremertun |
Author_xml | – sequence: 1 givenname: Pierre surname: Dillard fullname: Dillard, Pierre – sequence: 2 givenname: Hakan surname: Köksal fullname: Köksal, Hakan – sequence: 3 givenname: Sarah surname: Josefsson fullname: Josefsson, Sarah – sequence: 4 givenname: Solrun Melkorka surname: Maggadottir fullname: Maggadottir, Solrun Melkorka – sequence: 5 givenname: Sylvie surname: Pollmann fullname: Pollmann, Sylvie – sequence: 6 givenname: Anne surname: Fåne fullname: Fåne, Anne – sequence: 7 givenname: Yngvild Nuvin surname: Blaker fullname: Blaker, Yngvild Nuvin – sequence: 8 givenname: Klaus surname: Beiske fullname: Beiske, Klaus – sequence: 9 givenname: Kanutte surname: Huse fullname: Huse, Kanutte – sequence: 10 givenname: Ane surname: Kolstad fullname: Kolstad, Ane – sequence: 11 givenname: Harald surname: Holte fullname: Holte, Harald – sequence: 12 givenname: Gunnar surname: Kvalheim fullname: Kvalheim, Gunnar – sequence: 13 givenname: Erlend Bremertun surname: Smeland fullname: Smeland, Erlend Bremertun – sequence: 14 givenname: June surname: Myklebust fullname: Myklebust, June – sequence: 15 givenname: Else Marit surname: Inderberg fullname: Inderberg, Else Marit – sequence: 16 givenname: Sebastien surname: Wälchli fullname: Wälchli, Sebastien |
BookMark | eNqdj9FKxDAQRQdZwa76CcL8QNakbWj1rVbFF0Fk30OMU7aSNmUShP69hlU_wKfhzr0Xzt3CZg4zAVwpuVNKt9dKV61o6lrvuudSqhuh6rI8geLvv4FCStkKXTflGWxj_PiWWkldgO3eYmLrEubSLb4wOT_Oo7Me3-mTfFgmmhOGAfv7qum7V9wLR95jOhDbZcUhMCYmm35zd0ffr9NyCJO9gNPB-kiXP_cc9OPDvn8SjkOMTINZeJwsr0ZJk_eYzG0ytznuMRmt-m_vC6QtVLY |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1538-7445.AM2019-1422 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 1422 |
ExternalDocumentID | 10_1158_1538_7445_AM2019_1422 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ |
ID | FETCH-crossref_primary_10_1158_1538_7445_AM2019_14223 |
ISSN | 0008-5472 |
IngestDate | Fri Aug 23 02:35:43 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-crossref_primary_10_1158_1538_7445_AM2019_14223 |
ParticipantIDs | crossref_primary_10_1158_1538_7445_AM2019_1422 |
PublicationCentury | 2000 |
PublicationDate | 2019-07-01 |
PublicationDateYYYYMMDD | 2019-07-01 |
PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2019 |
SSID | ssj0005105 |
Score | 4.679787 |
Snippet | Abstract
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 have produced remarkable clinical responses in patients with... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 1422 |
Title | Abstract 1422: Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma |
Volume | 79 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDI4GSIgL4ineyoHb1AJbsmzcxksINARoSNyqtOkArVrR6A7wI_lN2E2yhIcQ41JtXetm9Sc7cT7bhOw2UgBCgjX2eSwC1txXQYvJOFCqJmvJQSsWCheKnavG-R27uOf3lcq7x1oaFXGYvP2YV_IfrcI50CtmyU6g2bFQOAGfQb9wBA3D8U86bscYqEiKKoZYcG1_DfbLpjoqRwcqORcndXHcvq12A4zVV3XelWZrOrI5XHekf89eQc25MdqukkGSDqumPtBjuQGsmRylpcmy0IsrnGA7I82bvwbX6zi2l7g3f9Tov0hdR1v2HUBxP6L3YpLAPgWrO_LhQcIKunjSjcLybDjCbaasnw_70o9dlOlSNnZh7XEz4Ew37wlTZ4IF00UmrY3WDWcsFutR2fLUcYO08cV37Tly-_W7k-CY-DB-TtjulGNzt_tFub84yzGFsVw88WaEYiIUE2kxEYqZIjM10eIYDLi8cdXruaHU2n9tMspAzN6Po_HmSt6kp7tA5s1qhbY19BZJJR0skdmO4WMsE2kRSFHQIfXwRz380bxHDf6oxh81-KOAPzrGH16n8Uct_lYIPzvtHp8HdojRs66PEv36auqrZHqQD9I1QqVKRUOouuIwC4ZpUasnemAxmAAvpBhj6yScTPbGpDdskjkHyy0yXQxH6TZMMot4p9TcB5T7dQ0 |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+1422%3A+Preclinical+development+of+CD37CAR+T-cell+therapy+for+treatment+of+B-cell+lymphoma&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Dillard%2C+Pierre&rft.au=K%C3%B6ksal%2C+Hakan&rft.au=Josefsson%2C+Sarah&rft.au=Maggadottir%2C+Solrun+Melkorka&rft.date=2019-07-01&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=79&rft.issue=13_Supplement&rft.spage=1422&rft.epage=1422&rft_id=info:doi/10.1158%2F1538-7445.AM2019-1422&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2019_1422 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |